PDS Biotechnology Corp (PDSB)

Currency in USD
1.240
-0.040(-3.13%)
Closed·
1.220-0.020(-1.61%)
·
PDSB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PDSB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.1801.300
52 wk Range
0.8514.290
Key Statistics
Prev. Close
1.28
Open
1.29
Day's Range
1.18-1.3
52 wk Range
0.851-4.29
Volume
531.91K
Average Volume (3m)
520.87K
1-Year Change
-59.87%
Book Value / Share
0.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PDSB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.500
Upside
+504.84%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

PDS Biotechnology Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

PDS Biotechnology Corp Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

PDS Biotechnology Corp Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.21 beat forecast of -$0.22; stock rose 1.63% to $1.25 in premarket trading
  • Net loss increased to $9.4M from $8.3M YoY; cash balance decreased to $31.9M from $41.7M at end of 2024
  • Final data readout for VERSAL-two trial expected by end of 2025 or early 2026; VERSAL-three trial enrollment ongoing
  • Analyst targets range from $4.50 to $13.00, indicating significant upside potential despite current unprofitability
  • CEO highlighted potential of PDS0101 in head and neck cancer; CMO emphasized trial specificity compared to competitors
Last Updated: 13/08/2025, 14:00
Read Full Transcript

Compare PDSB to Peers and Sector

Metrics to compare
PDSB
Peers
Sector
Relationship
P/E Ratio
−1.6x−2.7x−0.6x
PEG Ratio
−0.060.030.00
Price/Book
3.6x2.2x2.6x
Price / LTM Sales
-131.3x3.3x
Upside (Analyst Target)
303.2%172.5%39.1%
Fair Value Upside
Unlock7.0%5.4%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.500
(+504.84% Upside)

Earnings

Latest Release
Aug 13, 2025
EPS / Forecast
-0.21 / -0.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PDSB Income Statement

People Also Watch

18.34
SRPT
+1.49%
189.15
ALAB
+5.55%
22.34
ARWR
+2.52%
0.802
CUE
-2.91%
1.940
CRBU
-2.02%

FAQ

What Stock Exchange Does PDS Biotech Trade On?

PDS Biotech is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for PDS Biotech?

The stock symbol for PDS Biotech is "PDSB."

What Is the PDS Biotech Market Cap?

As of today, PDS Biotech market cap is 56.63M.

What Is PDS Biotech's Earnings Per Share (TTM)?

The PDS Biotech EPS (TTM) is -0.91.

When Is the Next PDS Biotech Earnings Date?

PDS Biotech will release its next earnings report on 11 Nov 2025.

From a Technical Analysis Perspective, Is PDSB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has PDS Biotech Stock Split?

PDS Biotech has split 1 times.

How Many Employees Does PDS Biotech Have?

PDS Biotech has 24 employees.

What is the current trading status of PDS Biotech (PDSB)?

As of 29 Aug 2025, PDS Biotech (PDSB) is trading at a price of 1.240, with a previous close of 1.28. The stock has fluctuated within a day range of 1.180 to 1.300, while its 52-week range spans from 0.851 to 4.290.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.